Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityMinority InterestNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Cumberland Pharmaceuticals (CPIX) Liabilities from Discontinued Operations: 2019-2020

  • Cumberland Pharmaceuticals' Liabilities from Discontinued Operations was N/A to $1.2 million in Q1 2020 from the same period last year, while for Mar 2020 it was $1.2 million, marking a year-over-year change of. This contributed to the annual value of $2.2 million for FY2019, which is N/A change from last year.
  • Cumberland Pharmaceuticals' Liabilities from Discontinued Operations amounted to $1.2 million in Q1 2020, which was down 42.04% from $2.2 million recorded in Q4 2019.
  • In the past 5 years, Cumberland Pharmaceuticals' Liabilities from Discontinued Operations ranged from a high of $2.2 million in Q4 2019 and a low of $1.2 million during Q1 2020.
  • Over the past 2 years, Cumberland Pharmaceuticals' median Liabilities from Discontinued Operations value was $1.7 million (recorded in 2019), while the average stood at $1.7 million.